PLRX

Pliant Therapeutics Inc

Add to Watchlist

Advanced Chart

1.690

-0.04(-2.312%)1D

Overview
Forecast
Valuation
Earnings

Line

Candle

YTD

High

1.700

Open

1.700

VWAP

1.66

Vol

984.67K

Mkt Cap

103.74M

Low

1.600

Amount

1.64M

EV/EBITDA(TTM)

Total Shares

60.33M

-169.16M

EV/OCF(TTM)

P/S(TTM)

Pliant Therapeutics, Inc. is a late-stage biotechnology company, which is focused on discovering and developing novel therapies for the treatment of fibrosis and related diseases. The Company’s lead product candidate, bexotegrast (PLN-74809), is an oral, small molecule, dual selective inhibitor of avb6 and avb1 integrins that is in development in the lead indication for the treatment of idiopathic pulmonary fibrosis, or idiopathic pulmonary fibrosis (IPF). The Company’s second clinical program, PLN-101095, is a small molecule, dual selective inhibitor of integrins avb8 and avb1 for the treatment of solid tumors that are resistant to immune checkpoint inhibitors. Its Phase 1-ready program PLN-101325, is in development for treatment of muscular dystrophies, including Duchenne muscular dystrophy. PLN-101325 is a monoclonal antibody designed to act as an allosteric agonist of integrin a7b1.

Market Estimates

Earnings Estimates

Revenue

YoY Chg

EPS

YoYChg

FY2025Q4

FY2025Q3

FY2025Q2

-0.403

-50.86%

-0.479

-49.62%

-0.677

-26.39%

Estimates Revision

The market is revising Downward the revenue expectations for Pliant Therapeutics, Inc. (PLRX) for FY2025, with the revenue forecasts being adjusted by -37.66% over the past three months. During the same period, the stock price has changed by 18.18%.

Revenue Estimates for FY2025

Revise Downward

-37.66%

In Past 3 Month

EPS Estimates for FY2025

Revise Upward

+1.5%

In Past 3 Month

Stock Price

Go Up

+18.18%

In Past 3 Month

6 Analyst Rating

373.37% Upside

Wall Street analysts forecast PLRX stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for PLRX is 8.00 USD with a low forecast of 3.00 USD and a high forecast of 17.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

1 Buy

5 Hold

0 Sell

Hold

373.37% Upside

Current: 1.690

Low

3.00

Averages

8.00

High

17.00

373.37% Upside

Current: 1.690

Low

3.00

Averages

8.00

High

17.00

HC Wainwright & Co.

Ed Arce

Hold

Reiterates

n/a

2025-03-18

Reason

HC Wainwright & Co.

Ed Arce

Price Target

n/a

2025-03-18

Reiterates

Hold

Reason

Needham

Joseph Stringer

Strong Buy

Hold

Downgrades

$10

2025-03-04

Reason

Needham

Joseph Stringer

Price Target

$10

2025-03-04

Downgrades

Strong Buy

Hold

Reason

Wells Fargo

Tiago Fauth

Hold

Maintains

$4 → $3

2025-03-04

Reason

Wells Fargo

Tiago Fauth

Price Target

$4 → $3

2025-03-04

Maintains

Hold

Reason

Cantor Fitzgerald

Pete Stavropoulos

Hold

Initiates

n/a

2025-03-04

Reason

Cantor Fitzgerald

Pete Stavropoulos

Price Target

n/a

2025-03-04

Initiates

Hold

Reason

Cantor Fitzgerald reinstated coverage of Pliant Therapeutics with a Neutral rating and no price target. The company is discontinuing the Pase 2b BEACON-IPF study of bexotegrast in idiopathic pulmonary fibrosis, the analyst tells investors in a research note. The firm says that while Pliant has two additional clinical stage programs and a third Phase 1-ready asset, without clear visibility on program prioritization, it remains on the sidelines.

RBC Capital

Brian Abrahams

Hold

Maintains

$4 → $3

2025-03-04

Reason

RBC Capital

Brian Abrahams

Price Target

$4 → $3

2025-03-04

Maintains

Hold

Reason

Citigroup

David Lebowitz

Hold

Maintains

$4 → $1.5

2025-03-04

Reason

Citigroup

David Lebowitz

Price Target

$4 → $1.5

2025-03-04

Maintains

Hold

Reason

Citi lowered the firm's price target on Pliant Therapeutics to $1.50 from $4 and keeps a Neutral rating on the shares. The company reported Q4 earnings after announcing it had discontinued the Phase 2b BEACON-IPF trial for bexotegrast in idiopathic pulmonary fibrosis after an outside expert panel completed an secondary review and concurred with the Data Safety Monitoring Board's recommendation, the analyst tells investors in a research note. Post the update, Citi substantially reduce its bexotegrast estimates, delaying a timeline of potential launch and lowering its probability of success to 20% from 40%.

See All Ratings

Valuation Metrics

The current forward P/E ratio for Pliant Therapeutics Inc (PLRX.O) is -0.80, compared to its 5-year average forward P/E of -5.51. For a more detailed relative valuation and DCF analysis to assess Pliant Therapeutics Inc 's fair value, click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

N/A

5Y Average PE

-5.51

Current PE

-0.80

Overvalued PE

-2.37

Undervalued PE

-8.66

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

N/A

5Y Average EV/EBITDA

-2.72

Current EV/EBITDA

1.07

Overvalued EV/EBITDA

0.31

Undervalued EV/EBITDA

-5.74

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

Fair

5Y Average PS

305.37

Current PS

52.18

Overvalued PS

591.23

Undervalued PS

19.50